BLOOMINGTON, Ind. — The city of Bloomington is further growing its role as a critical site for the mass production of the COVID-19 vaccine. Massachusetts-based Moderna Inc. (Nasdaq: MRNA) says it has selected Baxter International Inc. (NYSE: BAX) to fill and finish approximately as many as 90 million doses of its vaccine in the Monroe County city.
The work will take place this year at the Baxter BioPharma Solutions facility in Bloomington.
“We have seen a remarkable demonstration of scientific and health care expertise in the effort to develop vaccines for COVID-19,” said Marie Keeley, vice president, Baxter BioPharma Solutions. “Baxter is honored to provide our deep expertise in vaccine manufacturing to help partners like Moderna bolster the supply of their vaccine.”
As Inside INdiana Business has previously reported, Moderna is also partnering with New Jersey-based Catalent Inc. (NYSE: CTLT) to produce millions of doses of the vaccine at the Bloomington facility. Catalent has also been manufacturing the Johnson & Johnson vaccine for more than a month at the Monroe County facility. It is now awaiting regulatory approval to begin distribution.
Baxter BioPharma Solutions has operated in Bloomington for approximately 20 years and employs more than 700 people on its 600,000 square-foot campus.
